Lung Non-Squamous Non-Small Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LNG111 MIFTS: 55	Lung Non-Squamous Non-Small Cell Carcinoma Categories: Cancer diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards integrated aliases for Lung Non-Squamous Non-Small Cell Carcinoma:

Name: Lung Non-Squamous Non-Small Cell Carcinoma ¹¹ ¹⁴

Non- Squamous Nsclc ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0080521

NCIt ⁴⁹ C135017

Sources

Summaries for Lung Non-Squamous Non-Small Cell Carcinoma

Disease Ontology: ¹¹ A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation.

MalaCards based summary: Lung Non-Squamous Non-Small Cell Carcinoma, also known as non- squamous nsclc, is related to lung cancer susceptibility 3 and exanthem. An important gene associated with Lung Non-Squamous Non-Small Cell Carcinoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Osimertinib and Afatinib have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and brain, and related phenotypes are Decreased viability and Increased cell migration

Sources

Related Diseases for Lung Non-Squamous Non-Small Cell Carcinoma

Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)

#	Related Disease	Score	Top Affiliating Genes
1	lung cancer susceptibility 3	29.3	VEGFA STK11 ROS1 KRAS KDR HRAS
2	exanthem	28.9	VEGFA PDCD1 MTUS2 MTUS1 KRAS HRAS
3	lung cancer	28.6	VEGFA TYMS STK11 ROS1 RET PDCD1
4	vulva verrucous carcinoma	10.4	PDCD1 CD274
5	thymus squamous cell carcinoma	10.4	MTUS2 MTUS1
6	heart leiomyosarcoma	10.3	EGFR ALK
7	urethra transitional cell carcinoma	10.3	EGFR ALK
8	pulmonary plasma cell granuloma	10.3	ROS1 ALK
9	trachea carcinoma in situ	10.3	KRAS HRAS
10	lymphoepithelioma-like carcinoma	10.3	EGFR CD274 ALK
11	common bile duct neoplasm	10.3	KRAS HRAS
12	signet ring lung adenocarcinoma	10.3	EML4 EGFR ALK
13	malignant giant cell tumor of the tendon sheath	10.3	ROS1 ALK
14	ampulla of vater benign neoplasm	10.3	KRAS HRAS
15	thyroid crisis	10.3	MTUS2 MTUS1
16	occipital lobe neoplasm	10.3	ROS1 EML4 ALK
17	bladder urachal carcinoma	10.3	KRAS HRAS
18	hepatic flexure cancer	10.3	KRAS HRAS
19	vaginal carcinosarcoma	10.3	KRAS HRAS
20	urachus cancer	10.3	KRAS HRAS
21	thyroid gland hurthle cell carcinoma	10.3	ROS1 EML4 ALK
22	epithelioid inflammatory myofibroblastic sarcoma	10.3	EML4 ALK
23	lung giant cell carcinoma	10.3	KRAS EGFR ALK
24	cryptogenic organizing pneumonia	10.3	MTUS2 MTUS1 CD274
25	main bronchus cancer	10.3	ROS1 RET ALK
26	descending colon cancer	10.3	KRAS HRAS
27	vaginal cancer	10.3	HRAS EGFR CD274
28	mucinous intrahepatic cholangiocarcinoma	10.3	KRAS HRAS
29	vulva squamous cell carcinoma	10.3	HRAS EGFR CD274
30	sigmoid neoplasm	10.3	KRAS HRAS
31	acneiform dermatitis	10.3	KRAS HRAS EGFR
32	mesenchymal cell neoplasm	10.3	ROS1 EML4 ALK
33	appendiceal neoplasm	10.3	KRAS HRAS
34	central nervous system hemangioma	10.3	VEGFA RET
35	dermatopathia pigmentosa reticularis	10.3	KRAS HRAS EGFR
36	orbital plasma cell granuloma	10.3	MTUS2 MTUS1 CTLA4
37	chronic orbital inflammation	10.3	MTUS2 MTUS1 CTLA4
38	pancreatic mucinous cystadenoma	10.3	KRAS HRAS
39	autoimmune myocarditis	10.3	MTUS2 CTLA4 CD274
40	transverse colon cancer	10.3	KRAS HRAS
41	lymphocytic colitis	10.3	PDCD1 MTUS2 CTLA4
42	lung adenoma	10.3	KRAS HRAS EGFR
43	malignant dermis tumor	10.2	HRAS CTLA4 CD274
44	vulvar melanoma	10.2	HRAS CTLA4 CD274
45	malignant skin fibrous histiocytoma	10.2	HRAS CTLA4 CD274
46	respiratory system benign neoplasm	10.2	KRAS HRAS EGFR
47	noonan syndrome-like disorder with loose anagen hair 1	10.2	KRAS HRAS
48	colon adenoma	10.2	KRAS HRAS EGFR
49	testicular spermatocytic seminoma	10.2	RET HRAS
50	central nervous system vasculitis	10.2	MTUS2 MTUS1 CTLA4

Graphical network of the top 20 diseases related to Lung Non-Squamous Non-Small Cell Carcinoma:

Sources

Symptoms & Phenotypes for Lung Non-Squamous Non-Small Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 16)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.76	HRAS KRAS EGFR
2	Decreased viability	GR00055-A-2	10.76	HRAS KRAS EGFR
3	Decreased viability	GR00055-A-3	10.76	KRAS
4	Decreased viability	GR00106-A-0	10.76	KRAS
5	Decreased viability	GR00221-A-1	10.76	HRAS KDR KRAS RET ROS1 ALK
6	Decreased viability	GR00221-A-2	10.76	HRAS KDR KRAS RET ROS1
7	Decreased viability	GR00221-A-3	10.76	HRAS KDR ERBB2
8	Decreased viability	GR00221-A-4	10.76	KDR RET ALK EGFR ERBB2
9	Decreased viability	GR00249-S	10.76	KDR ROS1 ALK
10	Decreased viability	GR00301-A	10.76	KRAS RET
11	Decreased viability	GR00342-S-1	10.76	ROS1
12	Decreased viability	GR00381-A-1	10.76	KRAS
13	Decreased viability	GR00402-S-2	10.76	RET
14	Increased cell migration	GR00055-A-1	9.26	KDR
15	Increased cell migration	GR00055-A-3	9.26	KDR
16	Increased cell viability after pRB stimulation	GR00230-A-1	8.92	EGFR ERBB2 RET STK11

MGI Mouse Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma:

⁴⁵ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.36	ABCG2 ALK CD274 CTLA4 EGFR ERBB2
2	neoplasm	MP:0002006	10.32	ALK EGFR ERBB2 HRAS KRAS MTUS1
3	normal	MP:0002873	10.31	ABCG2 ALK CTLA4 EGFR ERBB2 HRAS
4	endocrine/exocrine gland	MP:0005379	10.27	ALK CTLA4 EGFR ERBB2 HRAS KRAS
5	no phenotypic analysis	MP:0003012	10.26	CD274 EGFR HRAS KDR KRAS PDCD1LG2
6	cellular	MP:0005384	10.21	ABCG2 CD274 EGFR ERBB2 KDR KRAS
7	renal/urinary system	MP:0005367	10.2	ABCG2 EGFR HRAS KRAS MTUS1 PDCD1
8	muscle	MP:0005369	10.19	EGFR ERBB2 HRAS KDR KRAS PDCD1
9	digestive/alimentary	MP:0005381	10.18	ABCG2 CTLA4 EGFR ERBB2 HRAS KRAS
10	immune system	MP:0005387	10.15	ABCG2 CD274 CTLA4 EGFR KDR KRAS
11	cardiovascular system	MP:0005385	10.14	CTLA4 EGFR ERBB2 HRAS KDR KRAS
12	liver/biliary system	MP:0005370	10.13	ABCG2 CTLA4 EGFR KDR KRAS PDCD1
13	respiratory system	MP:0005388	10.06	ALK CTLA4 EGFR ERBB2 HRAS KDR
14	craniofacial	MP:0005382	10	EGFR ERBB2 HRAS KDR KRAS STK11
15	skeleton	MP:0005390	10	ALK CD274 CTLA4 EGFR ERBB2 HRAS
16	hematopoietic system	MP:0005397	9.97	ABCG2 CD274 CTLA4 EGFR ERBB2 KDR
17	mortality/aging	MP:0010768	9.86	ALK CD274 CTLA4 EGFR EML4 ERBB2
18	integument	MP:0010771	9.36	ABCG2 ALK CD274 CTLA4 EGFR ERBB2

Sources

Drugs & Therapeutics for Lung Non-Squamous Non-Small Cell Carcinoma

Drugs for Lung Non-Squamous Non-Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Osimertinib

Approved

Phase 4

1421373-65-0

71496458

Afatinib

Approved

Phase 4

439081-18-2, 850140-72-6

53445376 10184653

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Erlotinib

Approved, Investigational

Phase 3

183319-69-9, 183321-74-6

176870

Glutamic acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Maleic acid

Experimental, Investigational

Phase 3

110-16-7, 110-17-8

444266 444972

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Immunoglobulins

Phase 3

Antimetabolites

Phase 3

Antibodies

Phase 3

Immunosuppressive Agents

Phase 3

Immunologic Factors

Phase 3

Endothelial Growth Factors

Phase 3

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Ramucirumab

Approved, Investigational

Phase 2

947687-13-0

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Talazoparib

Approved, Investigational

Phase 2

1207456-01-6

135565082

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Ipilimumab

Approved

Phase 2

477202-00-9

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Ceritinib

Approved

Phase 2

1032900-25-6

57379345

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Nivolumab

Approved

Phase 2

946414-94-4

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Crizotinib

Approved, Investigational

Phase 2

877399-52-5

11626560

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Lexatumumab

Investigational

Phase 2

845816-02-6

Molgramostim

Investigational

Phase 2

99283-10-0

Rivoceranib

Investigational

Phase 2

811803-05-1

11315474

Pevonedistat

Investigational

Phase 2

905579-51-3

49831043

Ensartinib

Investigational

Phase 2

1365267-27-1, 1370651-20-9

56960447

Imetelstat

Investigational

Phase 2

868169-64-6

Vaccines

Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2

Folic Acid Antagonists

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Vitamin B Complex

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Immunoglobulin G

Phase 2

Protein Kinase Inhibitors

Phase 2

Interventional clinical trials:

(show top 50) (show all 61)

#	Name	Status	NCT ID	Phase	Drugs
1	A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control.	Unknown status	NCT03768037	Phase 4	Anlotinib plus Pemetrexed;Pemetrexed
2	An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy	Unknown status	NCT03778853	Phase 4	Anlotinib Hydrochloride
3	An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy	Unknown status	NCT03755869	Phase 4	Anlotinib
4	AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting	Recruiting	NCT04413201	Phase 4	Afatinib;Osimertinib
5	A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC	Completed	NCT00806923	Phase 3	Cisplatin;Gemcitabine;Placebo;bevacizumab [Avastin]
6	Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC	Completed	NCT02954172	Phase 3	Bevacizumab in Combination With Paclitaxel/Carboplatin;IBI305 in Combination with Paclitaxel/Carboplatin
7	A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin	Completed	NCT02810457	Phase 3	FKB238 (bevacizumab);Avastin (bevacizumab);Paclitaxel;Carboplatin
8	Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC	Completed	NCT01107626	Phase 3	Paclitaxel;Carboplatin;Pemetrexed Disodium Heptahydrate
9	Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)	Recruiting	NCT04181060	Phase 3	Osimertinib
10	EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis	Recruiting	NCT03793179	Phase 3	Carboplatin;Pemetrexed
11	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)	Recruiting	NCT04267848	Phase 3	Carboplatin;Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed Disodium
12	A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy	Recruiting	NCT04447118	Phase 3	Pyrotinib;Docetaxel
13	A Phase 3，Randomized，Open，Parallel Controlled, Multi-center Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab as a First-line Treatment on Patient With Advanced Non-squamous NSCLC	Recruiting	NCT05346952	Phase 3	TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
14	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment	Recruiting	NCT05184712	Phase 3	AK112 Injection;Placebo Injection
15	Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)	Active, not recruiting	NCT02193282	Phase 3	Erlotinib Hydrochloride
16	A RANDOMIZED, DOUBLE-BLIND BRIDGING SAFETY AND EFFICACY STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF CHINESE PARTICIPANTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER	Terminated	NCT04325698	Phase 3	PF-06439535 (CN);Bevacizumab-EU;Paclitaxel;Carboplatin
17	A Randomized, Double-blind, Phase 3 Bridging Study Evaluating the Safety and Efficacy of ABP 215 Compared With Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer	Withdrawn	NCT04466917	Phase 3	ABP 215;Bevacizumab;Paclitaxel;Carboplatin
18	A Randomized Phase II Trial of Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib	Unknown status	NCT04358562	Phase 2	Gefitinib;Anlotinib
19	Anlotinib Combined With Docetaxel as Second-line Treatment of Patients With Wild-type Advanced Non-squamous NSCLC	Unknown status	NCT03750916	Phase 2	Anlotinib Hydrochloride plus Docetaxel
20	A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR	Unknown status	NCT01755923	Phase 2	Gefitinib;Docetaxel
21	A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations	Completed	NCT01532089	Phase 2	Erlotinib;Erlotinib Hydrochloride
22	A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy	Completed	NCT02047344	Phase 2	Antroquinonol
23	Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabin/Cisplatin Plus Bevacizumab	Completed	NCT00536640	Phase 2	Erlotinib;Bevacizumab;Gemcitabine;Cisplatin
24	A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC	Completed	NCT00251524	Phase 2	Bevacizumab, Oxaliplatin, Pemetrexed
25	Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).	Completed	NCT01116219	Phase 2	bevacizumab, pemetrexed, cisplatin
26	A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC	Completed	NCT01496742	Phase 2	Placebo;RO5490258;bevacizumab [Avastin];cisplatin/carboplatin;paclitaxel;pemetrexed
27	A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC	Recruiting	NCT04310007	Phase 2	Cabozantinib S-malate;Docetaxel;Gemcitabine Hydrochloride;Nab-paclitaxel;Paclitaxel
28	A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer	Recruiting	NCT05017025	Phase 1, Phase 2	Aurora A Kinase Inhibitor LY3295668;Osimertinib
29	A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)	Recruiting	NCT04625647	Phase 2	Sotorasib
30	A Phase II Randomized Study of Safety and Efficacy of a Multiple Antigen Vaccine (STEMVAC) in NonSquamous Non-Small-Cell Lung Cancer Patients	Recruiting	NCT05242965	Phase 2
31	A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer	Recruiting	NCT05198830	Phase 2	Cisplatin;Methoxyamine;Pemetrexed
32	A Single-Arm Phase II Trial of Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy	Recruiting	NCT04670913	Phase 2	Camrelizumab;Apatinib
33	A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC	Recruiting	NCT04163432	Phase 2	Durvalumab;Pemetrexed;Carboplatin
34	TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked	Recruiting	NCT03786692	Phase 2	Arm A;Arm B
35	Phase II Randomized Trial of Carboplatin/Cisplatin+Pemetrexed+PD-1 Inhibitor+/- Bevacizumab in Stage IV Non-squamous NSCLC	Recruiting	NCT05267366	Phase 2	PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
36	A Phase II Two Cohorts Prospective Study to Evaluate the Efficacy and Safety of Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in Non-squamous NSCLC With EGFR Sensitizing Mutation Who Failed EGFR TKI Therapy	Recruiting	NCT04405674	Phase 2	Tislelizumab;Carboplatin;Pemetrexed;Bevacizumab;Nab paclitaxel
37	A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC	Recruiting	NCT04958811	Phase 2	Tiragolumab;Atezolizumab;Bevacizumab
38	A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)	Active, not recruiting	NCT04173507	Phase 2	Avelumab;Talazoparib;Talazoparib Tosylate
39	A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy	Active, not recruiting	NCT03965689	Phase 2	Carboplatin;Paclitaxel;Pevonedistat
40	A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC	Active, not recruiting	NCT03468985	Phase 2	Cabozantinib;Cabozantinib S-malate
41	A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol	Active, not recruiting	NCT03737994	Phase 2	Alectinib;Brigatinib;Carboplatin;Ceritinib;Cisplatin;Crizotinib;Ensartinib;Lorlatinib;Pemetrexed
42	A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance	Active, not recruiting	NCT04245085	Phase 2	Atezolizumab;Bevacizumab;Carboplatin;Paclitaxel;Pemetrexed
43	A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response	Active, not recruiting	NCT02955758	Phase 2
44	Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed for Untreated EGFR+ and High PD-L1 Expression Non-squamous NSCLC :a Phase II, Single-center, Single Arm Study	Not yet recruiting	NCT05394233	Phase 2	Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
45	A Single-Arm Phase 2 Study to Investigate Bintrafusp Alfa With Platinum-Pemetrexed for TKI-Resistant EGFR-Mutant NSCLC	Terminated	NCT04971187	Phase 2	Bintrafusp Alfa;Pemetrexed;Carboplatin;Cisplatin
46	A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy	Terminated	NCT02452463	Phase 2	Nintedanib
47	A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer	Terminated	NCT00369070	Phase 2	AMG 706;Paclitaxel;Carboplatin
48	A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor	Terminated	NCT02454842	Phase 2	TH-4000 (Tarloxotinib)
49	Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor	Terminated	NCT03041181	Phase 2	Docetaxel;Nivolumab;Gemcitabine;Pemetrexed
50	S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy	Terminated	NCT02134912	Phase 2	crizotinib;pemetrexed disodium

Search NIH Clinical Center for Lung Non-Squamous Non-Small Cell Carcinoma

Sources

Genetic Tests for Lung Non-Squamous Non-Small Cell Carcinoma

Sources

Anatomical Context for Lung Non-Squamous Non-Small Cell Carcinoma

Organs/tissues related to Lung Non-Squamous Non-Small Cell Carcinoma:

MalaCards : Lung, Endothelial, Brain, Lymph Node, Thyroid, Bone, Neutrophil

Sources

Publications for Lung Non-Squamous Non-Small Cell Carcinoma

Articles related to Lung Non-Squamous Non-Small Cell Carcinoma:

(show top 50) (show all 473)

#	Title	Authors	PMID	Year
1	Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. ⁶²	Liang J...Guo D	36128737	2022
2	A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. ⁶²	Zhou L...Ren X	35995696	2022
3	Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety. ⁶²	Cao H...Lu Y	35851702	2022
4	Is video-assisted thoracoscopic surgery comparable with thoracotomy in perioperative and long-term survival outcomes for non-small-cell lung cancer after neoadjuvant treatment? ⁶²	Wang YF...Zhou Q	36409029	2022
5	Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer. ⁶²	Visser E...Scharnhorst V	36413862	2022
6	Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer. ⁶²	Wan Y...Wu G	36401689	2022
7	Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. ⁶²	Gogishvili M...Rietschel P	36008722	2022
8	Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ⁶²	Soo R...Stahel R	35988454	2022
9	First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study. ⁶²	Huang LY...Lee PC	36314347	2022
10	Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. ⁶²	Jung HA...Park K	35838647	2022
11	Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. ⁶²	Wang Y...Liu H	35641819	2022
12	Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. ⁶²	Awad MM...Srinivasan L	36027916	2022
13	Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC. ⁶²	Leung CSK...Van den Eynde BJ	36027917	2022
14	EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study. ⁶²	Helland A...Enerly E	36155129	2022
15	Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. ⁶²	Murugesan K...Huang RSP	35598202	2022
16	Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis. ⁶²	Tian Y...Yu J	35290596	2022
17	Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China. ⁶²	Xie Q...Li Q	36194670	2022
18	Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations. ⁶²	Sun S...Yu H	35835883	2022
19	Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy. ⁶²	Ebot EM...Albacker LA	35739333	2022
20	Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis. ⁶²	Xiao X...Jia Y	35836506	2022
21	Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC. ⁶²	Kim IA...Lee KY	35681723	2022
22	Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. ⁶²	Govindan R...Bach BA	35331641	2022
23	Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction. ⁶²	Belluomini L...Milella M	34470722	2022
24	Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study. ⁶²	Garcia BNC...van der Wekken AJ	35349855	2022
25	Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. ⁶²	Englmeier F...Nagels K	35532791	2022
26	Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. ⁶²	Kazdal D...Hofman P	34997651	2022
27	Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China. ⁶²	Jiang Y...Wang X	32737070	2022
28	Sintilimab for the treatment of non-small cell lung cancer. ⁶²	Zhang L...He J	35436956	2022
29	Sugemalimab: First Approval. ⁶²	Dhillon S...Duggan S	35298827	2022
30	A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. ⁶²	Ten Berge DMHJ...Kloover JS	35248841	2022
31	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. ⁶²	Lecuelle J...Ghiringhelli F	35277462	2022
32	Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis. ⁶²	Chai Y...Duan J	35329978	2022
33	Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. ⁶²	Cho BC...Park K	35323374	2022
34	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial. ⁶²	Souquet PJ...Perol M	35051725	2022
35	Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. ⁶²	Stroyakovskiy DL...Kryukov F	35105329	2022
36	A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion. ⁶²	Di W...Jian F	35080187	2022
37	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. ⁶²	Zhou C...Yang J	35038432	2022
38	Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up. ⁶²	Finall A...Mullard A	35042754	2022
39	Molecular analysis in cytological samples obtained by endobronchial or oesophageal ultrasound guided needle aspiration in non-small cell lung cancer. ⁶²	Centeno C...Andreo Garcia F	32507497	2022
40	Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. ⁶²	Liu W...Chen P	35799785	2022
41	Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. ⁶²	Mileham KF...Silvestri GA	34921524	2022
42	The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. ⁶²	Ezeife DA...Leighl NB	35923926	2022
43	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. ⁶²	Huo G...Chen P	35479081	2022
44	Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. ⁶²	Kerrigan K...Puri S	35060001	2022
45	Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study. ⁶²	Bilger G...Decroisette C	35694190	2022
46	Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer. ⁶²	Stokke K...Halvorsen TO	35342321	2022
47	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50. ⁶²	Attili I...de Marinis F	36033444	2022
48	Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer. ⁶²	Zheng Z...Cai H	36172187	2022
49	Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study. ⁶²	Dong X...Wu G	36275698	2022
50	MYL-1402O: A Bevacizumab Biosimilar. ⁶²	Lee A	34910269	2022

Sources

Genes for Lung Non-Squamous Non-Small Cell Carcinoma

Genes related to Lung Non-Squamous Non-Small Cell Carcinoma (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	8.61	DISEASES inferred ¹⁴
2	CD274	CD274 Molecule	Protein Coding	8.25	DISEASES inferred ¹⁴
3	EGFR	Epidermal Growth Factor Receptor	Protein Coding	8.25	DISEASES inferred ¹⁴
4	ROS1	ROS Proto-Oncogene 1, Receptor Tyrosine Kinase	Protein Coding	7.89	DISEASES inferred ¹⁴
5	MTUS2	Microtubule Associated Scaffold Protein 2	Protein Coding	7.41	DISEASES inferred ¹⁴
6	MTUS1	Microtubule Associated Scaffold Protein 1	Protein Coding	7.4	DISEASES inferred ¹⁴
7	PDCD1	Programmed Cell Death 1	Protein Coding	7.28	DISEASES inferred ¹⁴
8	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	7.1	DISEASES inferred ¹⁴
9	EML4	EMAP Like 4	Protein Coding	6.95	DISEASES inferred ¹⁴
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.92	DISEASES inferred ¹⁴
11	RET	Ret Proto-Oncogene	Protein Coding	6.8	DISEASES inferred ¹⁴
12	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	6.71	DISEASES inferred ¹⁴
13	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	6.64	DISEASES inferred ¹⁴
14	GART	Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase	Protein Coding	6.59	DISEASES inferred ¹⁴
15	PDCD1LG2	Programmed Cell Death 1 Ligand 2	Protein Coding	6.57	DISEASES inferred ¹⁴
16	TYMS	Thymidylate Synthetase	Protein Coding	6.53	DISEASES inferred ¹⁴
17	KDR	Kinase Insert Domain Receptor	Protein Coding	6.43	DISEASES inferred ¹⁴
18	STK11	Serine/Threonine Kinase 11	Protein Coding	6.36	DISEASES inferred ¹⁴
19	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.18	DISEASES inferred ¹⁴
20	ABCG2	ATP Binding Cassette Subfamily G Member 2 (Junior Blood Group)	Protein Coding	6.04	DISEASES inferred ¹⁴
21	DHFR	Dihydrofolate Reductase	Protein Coding	5.94	DISEASES inferred ¹⁴
22	CD8A	CD8a Molecule	Protein Coding	5.85	DISEASES inferred ¹⁴
23	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	5.77	DISEASES inferred ¹⁴

Sources

Variations for Lung Non-Squamous Non-Small Cell Carcinoma

Cosmic variations for Lung Non-Squamous Non-Small Cell Carcinoma:

⁸ (show top 50) (show all 17775)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM98616023	ZZEF1	lung,NS,carcinoma,small cell carcinoma	c.4892G>T	p.G1631V	17:4059282-4059282	6
2	COSM132740059	ZYG11B	lung,NS,carcinoma,small cell carcinoma	c.1635G>C	p.M545I	1:52801968-52801968	6
3	COSM86240454	ZYG11B	lung,NS,carcinoma,small cell carcinoma	c.1635G>C	p.M545I	1:52801968-52801968	6
4	COSM86919234	ZSWIM4	lung,NS,carcinoma,small cell carcinoma	c.944G>T	p.R315L	19:13809152-13809152	6
5	COSM88262283	ZRSR2	lung,NS,carcinoma,small cell carcinoma	c.1180G>A	p.E394K	23:15822973-15822973	6
6	COSM143073175	ZRANB2	lung,NS,carcinoma,small cell carcinoma	c.17T>C	p.F6S	1:71080979-71080979	6
7	COSM97720347	ZRANB2	lung,NS,carcinoma,small cell carcinoma	c.17T>C	p.F6S	1:71080979-71080979	6
8	COSM87171618	ZRANB2	lung,NS,carcinoma,small cell carcinoma	c.17T>C	p.F6S	1:71080979-71080979	6
9	COSM137271685	ZP2	lung,NS,carcinoma,small cell carcinoma	c.1581C>T	p.P527=	16:21201455-21201455	6
10	COSM137165710	ZP2	lung,NS,carcinoma,small cell carcinoma	c.1608C>T	p.P536=	16:21201455-21201455	6
11	COSM131896932	ZNF84	lung,NS,carcinoma,small cell carcinoma	c.239-5340A>G	p.?	12:133057739-133057739	6
12	COSM101262318	ZNF84	lung,NS,carcinoma,small cell carcinoma	c.1024A>G	p.T342A	12:133057739-133057739	6
13	COSM91416826	ZNF84	lung,NS,carcinoma,small cell carcinoma	c.1024A>G	p.T342A	12:133057739-133057739	6
14	COSM133556674	ZNF84	lung,NS,carcinoma,small cell carcinoma	c.1021A>G	p.T341A	12:133057739-133057739	6
15	COSM130336034	ZNF84	lung,NS,carcinoma,small cell carcinoma	c.1024A>G	p.T342A	12:133057739-133057739	6
16	COSM98062407	ZNF831	lung,NS,carcinoma,small cell carcinoma	c.1027G>C	p.D343H	20:59192046-59192046	6
17	COSM149927805	ZNF831	lung,NS,carcinoma,small cell carcinoma	c.1027G>C	p.D343H	20:59192046-59192046	6
18	COSM92021621	ZNF804B	lung,NS,carcinoma,small cell carcinoma	c.522C>A	p.P174=	7:89333504-89333504	6
19	COSM142170486	ZNF804B	lung,NS,carcinoma,small cell carcinoma	c.273C>A	p.P91=	7:89333504-89333504	6
20	COSM142179504	ZNF804B	lung,NS,carcinoma,small cell carcinoma	c.3504G>C	p.L1168=	7:89336735-89336735	6
21	COSM142171430	ZNF804B	lung,NS,carcinoma,small cell carcinoma	c.3412G>C	p.A1138P	7:89336643-89336643	6
22	COSM92048538	ZNF804B	lung,NS,carcinoma,small cell carcinoma	c.3753G>C	p.L1251=	7:89336735-89336735	6
23	COSM92024942	ZNF804B	lung,NS,carcinoma,small cell carcinoma	c.3661G>C	p.A1221P	7:89336643-89336643	6
24	COSM88575001	ZNF804A	lung,NS,carcinoma,small cell carcinoma	c.862A>T	p.K288*	2:184936258-184936258	6
25	COSM88576053	ZNF804A	lung,NS,carcinoma,small cell carcinoma	c.3281C>T	p.S1094F	2:184938677-184938677	6
26	COSM143615605	ZNF804A	lung,NS,carcinoma,small cell carcinoma	c.607A>T	p.K203*	2:184936258-184936258	6
27	COSM143615950	ZNF804A	lung,NS,carcinoma,small cell carcinoma	c.3026C>T	p.S1009F	2:184938677-184938677	6
28	COSM84362584	ZNF777	lung,NS,carcinoma,small cell carcinoma	c.1998C>T	p.C666=	7:149432274-149432274	6
29	COSM91557035	ZNF746	lung,NS,carcinoma,small cell carcinoma	c.887C>T	p.A296V	7:149475432-149475432	6
30	COSM151200494	ZNF746	lung,NS,carcinoma,small cell carcinoma	c.932C>T	p.A311V	7:149475432-149475432	6
31	COSM114445791	ZNF746	lung,NS,carcinoma,small cell carcinoma	c.890C>T	p.A297V	7:149475432-149475432	6
32	COSM97007058	ZNF711	lung,NS,carcinoma,small cell carcinoma	c.173A>T	p.D58V	23:85255352-85255352	6
33	COSM87004058	ZNF711	lung,NS,carcinoma,small cell carcinoma	c.1371G>T	p.E457D	23:85270913-85270913	6
34	COSM96524071	ZNF711	lung,NS,carcinoma,small cell carcinoma	c.1371G>T	p.E457D	23:85270913-85270913	6
35	COSM87004493	ZNF711	lung,NS,carcinoma,small cell carcinoma	c.173A>T	p.D58V	23:85255352-85255352	6
36	COSM97006621	ZNF711	lung,NS,carcinoma,small cell carcinoma	c.1509G>T	p.E503D	23:85270913-85270913	6
37	COSM96524396	ZNF711	lung,NS,carcinoma,small cell carcinoma	c.173A>T	p.D58V	23:85255352-85255352	6
38	COSM130605261	ZNF7	lung,NS,carcinoma,small cell carcinoma	c.701G>C	p.G234A	8:144842096-144842096	6
39	COSM89464457	ZNF7	lung,NS,carcinoma,small cell carcinoma	c.281-3883G>C	p.?	8:144842096-144842096	6
40	COSM129405109	ZNF7	lung,NS,carcinoma,small cell carcinoma	c.248-3883G>C	p.?	8:144842096-144842096	6
41	COSM110827987	ZNF7	lung,NS,carcinoma,small cell carcinoma	c.1022G>C	p.G341A	8:144842096-144842096	6
42	COSM130688921	ZNF7	lung,NS,carcinoma,small cell carcinoma	c.989G>C	p.G330A	8:144842096-144842096	6
43	COSM141336221	ZNF667	lung,NS,carcinoma,small cell carcinoma	c.132G>T	p.L44F	19:56460717-56460717	6
44	COSM122146768	ZNF667	lung,NS,carcinoma,small cell carcinoma	c.132G>T	p.L44F	19:56460717-56460717	6
45	COSM85394970	ZNF667	lung,NS,carcinoma,small cell carcinoma	c.132G>T	p.L44F	19:56460717-56460717	6
46	COSM92174992	ZNF660	lung,NS,carcinoma,small cell carcinoma	c.575G>A	p.C192Y	3:44594768-44594768	6
47	COSM86006104	ZNF653	lung,NS,carcinoma,small cell carcinoma	c.808C>T	p.P270S	19:11487655-11487655	6
48	COSM86006115	ZNF653	lung,NS,carcinoma,small cell carcinoma	c.346C>T	p.R116W	19:11496163-11496163	6
49	COSM105713312	ZNF638	lung,NS,carcinoma,small cell carcinoma	c.1926G>A	p.K642=	2:71365637-71365637	6
50	COSM105035820	ZNF638	lung,NS,carcinoma,small cell carcinoma	c.1926G>A	p.K642=	2:71365637-71365637	6

Sources

Expression for Lung Non-Squamous Non-Small Cell Carcinoma

Search GEO for disease gene expression data for Lung Non-Squamous Non-Small Cell Carcinoma.

Sources

Pathways for Lung Non-Squamous Non-Small Cell Carcinoma

Pathways related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.83	ALK EGFR ERBB2 HRAS KDR KRAS
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.82	VEGFA PDCD1 KRAS KDR HRAS ERBB2
3	Signal Transduction ⁶⁶	13.76	ALK CD274 EGFR ERBB2 HRAS KDR
4	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.71	VEGFA ROS1 KRAS KDR HRAS ERBB2
5	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.65	ALK EGFR ERBB2 HRAS KDR KRAS
6	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.55	VEGFA ROS1 KRAS KDR HRAS ERBB2
7	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.42	ROS1 KRAS KDR HRAS ERBB2 EGFR
8	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.35	ALK EGFR EML4 ERBB2 HRAS KDR
9	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.33	ROS1 KRAS KDR HRAS ERBB2 EGFR
10	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.22	VEGFA ROS1 KRAS KDR HRAS ERBB2
11	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.06	STK11 KRAS KDR HRAS EGFR ALK
12	Actin Nucleation by ARP-WASP Complex ⁶⁴ Show member pathways Actin Nucleation and Branching ⁶⁴ CDC42 Pathway ⁶⁴ RhoA Pathway ⁶⁴	12.96	ALK EGFR ERBB2 KDR ROS1
13	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.94	EGFR HRAS KDR KRAS STK11 VEGFA
14	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.73	ALK CD274 EGFR ERBB2 HRAS KDR
15	Malignant pleural mesothelioma ⁷⁴	12.7	VEGFA KDR HRAS EGFR CD274
16	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.54	VEGFA KRAS KDR HRAS ERBB2 EML4
17	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.5	KRAS HRAS ERBB2 EGFR
18	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.47	KRAS HRAS ERBB2 EGFR
19	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.43	VEGFA KRAS KDR HRAS EGFR
20	RhoGDI Pathway ⁶⁴ Show member pathways Fc-GammaR-Mediated Phagocytosis in Macrophages ⁶⁴	12.41	VEGFA KDR HRAS EGFR
21	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.41	VEGFA KRAS KDR HRAS
22	CD28 co-stimulation ⁶⁶ Show member pathways Activation of AKT2 ⁶⁶ CD28 dependent PI3K/Akt signaling ⁶⁶ CD28 dependent Vav1 pathway ⁶⁶ Costimulation by the CD28 family ⁶⁶ CTLA4 Signaling ⁶⁴ VEGFR2 mediated vascular permeability ⁶⁶	12.4	PDCD1LG2 PDCD1 CTLA4 CD274
23	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.4	KRAS KDR HRAS ERBB2 EGFR
24	Signaling by VEGF ⁶⁶ Show member pathways VEGFA-VEGFR2 Pathway ⁶⁶	12.32	VEGFA KRAS KDR HRAS
25	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.32	ALK EGFR ERBB2 HRAS KDR KRAS
26	Ras signaling ⁷⁴	12.25	KRAS KDR HRAS EGFR
27	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.25	KRAS HRAS ERBB2 EGFR
28	Focal adhesion ⁷⁴	12.24	VEGFA KDR HRAS ERBB2 EGFR
29	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.19	KRAS KDR HRAS ERBB2 EGFR
30	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.17	VEGFA KRAS KDR HRAS EGFR
31	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.15	KRAS HRAS ERBB2 EGFR
32	Integrated breast cancer pathway ⁷⁴	12.13	VEGFA STK11 KRAS EGFR
33	CCR3 Pathway in Eosinophils ⁶⁴ Show member pathways VEGF and S-1P Signaling ⁶⁴	12.11	VEGFA KRAS KDR HRAS
34	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.06	KRAS HRAS ERBB2 EGFR
35	mTOR Signaling ⁶⁵	12.05	STK11 KRAS KDR ERBB2 EGFR
36	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.03	KRAS HRAS ERBB2 EGFR
37	Tyrosine Kinases / Adaptors ³	12.02	ROS1 RET KDR ERBB2 EGFR ALK
38	Gastrin signaling pathway ⁷⁴	11.96	VEGFA KRAS HRAS EGFR
39	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.95	KRAS HRAS ERBB2 EGFR
40	DNA damage response (only ATM dependent) ⁷⁴	11.93	KRAS HRAS ERBB2
41	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.91	KRAS HRAS EGFR
42	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.86	EGFR ERBB2 VEGFA
43	Clear cell renal cell carcinoma pathways ⁷⁴	11.83	VEGFA KDR EGFR
44	Phosphorylation of CD3 and TCR zeta chains ⁶⁶ Show member pathways Generation of second messenger molecules ⁶⁶ PD-1 signaling ⁶⁶	11.8	PDCD1LG2 PDCD1 CD274
45	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.76	HRAS KDR KRAS RET
46	Transcription Ligand-dependent activation of the ESR1/SP pathway ²² Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²²	11.73	EGFR TYMS VEGFA
47	SHP2 signaling ⁶¹	11.6	EGFR KDR VEGFA
48	NRP1-triggered signaling pathways in pancreatic cancer ⁷⁴	11.59	VEGFA KDR EGFR
49	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.58	KRAS HRAS ERBB2 EGFR
50	Signaling by PDGFR in disease ⁶⁶ Show member pathways Signaling by cytosolic PDGFRA and PDGFRB fusion proteins ⁶⁶ Signaling by membrane-tethered fusions of PDGFRA or PDGFRB ⁶⁶ Signaling by PDGFRA extracellular domain mutants ⁶⁶ Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants ⁶⁶	11.57	KRAS KDR HRAS

Sources

GO Terms for Lung Non-Squamous Non-Small Cell Carcinoma

Cellular components related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016021	10.22	ABCG2 ALK CD274 CTLA4 EGFR ERBB2
2	membrane	GO:0016020	10.22	ABCG2 ALK CD274 CTLA4 EGFR EML4
3	plasma membrane	GO:0005886	10.18	ROS1 RET KDR ERBB2 EGFR CTLA4
4	plasma membrane	GO:0005887	10.18	ROS1 RET KDR ERBB2 EGFR CTLA4
5	receptor complex	GO:0043235	9.4	ROS1 RET KDR ERBB2 EGFR ALK

Biological processes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.51	ALK CD274 EGFR ERBB2 HRAS KRAS
2	positive regulation of cell population proliferation	GO:0008284	10.38	VEGFA KRAS KDR HRAS ERBB2 EGFR
3	cell surface receptor signaling pathway	GO:0007166	10.3	PDCD1LG2 HRAS ERBB2 EGFR CD274
4	protein phosphorylation	GO:0006468	10.26	ALK EGFR ERBB2 KDR RET ROS1
5	positive regulation of cell migration	GO:0030335	10.23	VEGFA RET KDR HRAS EGFR CD274
6	protein autophosphorylation	GO:0046777	10.21	STK11 KDR ERBB2 EGFR ALK
7	positive regulation of protein phosphorylation	GO:0001934	10.21	EGFR ERBB2 HRAS KDR KRAS VEGFA
8	MAPK cascade	GO:0000165	10.19	EGFR HRAS KRAS RET
9	positive regulation of MAPK cascade	GO:0043410	10.14	VEGFA RET KDR HRAS ERBB2 ALK
10	positive regulation of MAP kinase activity	GO:0043406	10.1	VEGFA HRAS ERBB2 EGFR
11	phosphorylation	GO:0016310	10.08	ALK EGFR ERBB2 KDR RET ROS1
12	negative regulation of T cell proliferation	GO:0042130	10.06	PDCD1LG2 CTLA4 CD274
13	peptidyl-tyrosine phosphorylation	GO:0018108	10.06	ALK EGFR ERBB2 KDR RET ROS1
14	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	10.03	ROS1 RET KDR ERBB2 EGFR ALK
15	positive regulation of epithelial cell proliferation	GO:0050679	10.02	VEGFA KDR HRAS ERBB2 EGFR
16	regulation of ERK1 and ERK2 cascade	GO:0070372	10.01	ROS1 ERBB2 EGFR
17	positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway	GO:0038033	9.87	VEGFA KDR
18	vascular endothelial growth factor receptor-2 signaling pathway	GO:0036324	9.86	VEGFA KDR
19	positive regulation of phosphorylation	GO:0042327	9.85	VEGFA KDR EGFR
20	positive regulation of kinase activity	GO:0033674	9.73	ROS1 RET KDR ERBB2 EGFR ALK
21	peptidyl-tyrosine autophosphorylation	GO:0038083	9.7	ALK EGFR KDR ROS1
22	multicellular organism development	GO:0007275	9.1	ROS1 RET KDR ERBB2 EGFR ALK

Molecular functions related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transferase activity	GO:0016740	10.02	TYMS STK11 ROS1 RET KDR GART
2	protein tyrosine kinase activity	GO:0004713	9.93	ALK EGFR ERBB2 KDR RET ROS1
3	kinase activity	GO:0016301	9.87	STK11 ROS1 RET KDR ERBB2 EGFR
4	protein kinase activity	GO:0004672	9.8	STK11 ROS1 RET KDR ERBB2 EGFR
5	nucleotide binding	GO:0000166	9.7	STK11 ROS1 RET KRAS KDR HRAS
6	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.4	ROS1 RET KDR ERBB2 EGFR ALK